PMID- 34342379
OWN - NLM
STAT- MEDLINE
DCOM- 20220117
LR  - 20220117
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 35
IP  - 9
DP  - 2021 Sep
TI  - Reference interval and the role of plasma oligomeric beta amyloid in screening of 
      risk groups for cognitive dysfunction at health checkups.
PG  - e23933
LID - 10.1002/jcla.23933 [doi]
LID - e23933
AB  - BACKGROUND: Alzheimer's disease (AD) has a prolonged preclinical stage 
      characterized by cognitive dysfunction. Simple, reliable, and noninvasive 
      biomarkers reflecting the pathogenesis of AD are needed for screening cognitive 
      dysfunction in primary health care. The aims of this study were to determine (1) 
      the potential utility of the Multimer Detection System-Oligomeric Amyloid-beta 
      (MDS-OAbeta) value in cognitive assessments and (2) the reference interval (RI) of 
      plasma MDS-OAbeta values in the general population. METHODS: This prospective study 
      consecutively recruited 1,594 participants who underwent health checkups 
      including cognitive function examination at 16 health-promotion centers in Korea 
      between December 2020 and January 2021. The inBlood(TM) OAbeta test (PeopleBio, 
      Gyeonggi-do, Republic of Korea) was utilized to quantify MDS-OAbeta values in 
      plasma. The reference subjects were obtained among those with normal general 
      cognition on cognitive screening tools. RIs were established according to the 
      CLSI C28-A3 guidelines. RESULTS: The median MDS-OAbeta value was higher in subjects 
      with Korean Dementia Screening Questionnaire-Cognition (KDSQ-C) scores >/=8 than in 
      those with KDSQ-C scores of 6-7 (P = 0.013). The median MDS-OAbeta value was higher 
      in subjects with Mini-Mental State Examination for Dementia Screening (MMSE-DS) 
      scores of 21-26 than in those with MMSE-DS scores >/=27 (P = 0.011). The RI 
      (one-side upper 95th percentile) of the MDS-OAbeta value was 0.80 ng/mL (95% 
      confidence interval = 0.78-0.82) in those aged >/=50 years. CONCLUSIONS: The plasma 
      MDS-OAbeta value reflects cognitive function as assessed using the KDSQ-C and 
      MMSE-DS. RIs obtained from a large and cognitively healthy community-based sample 
      are presented.
CI  - (c) The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Nah, Eun-Hee
AU  - Nah EH
AUID- ORCID: 0000-0003-0637-4364
AD  - Department of Laboratory Medicine and Health Promotion Research Institute, Korea 
      Association of Health Promotion, Seoul, Korea.
FAU - Cho, Seon
AU  - Cho S
AD  - Department of Laboratory Medicine and Health Promotion Research Institute, Korea 
      Association of Health Promotion, Seoul, Korea.
FAU - Park, Hyeran
AU  - Park H
AD  - Department of Laboratory Medicine and Health Promotion Research Institute, Korea 
      Association of Health Promotion, Seoul, Korea.
FAU - Noh, Dongwon
AU  - Noh D
AD  - Department of Laboratory Medicine and Health Promotion Research Institute, Korea 
      Association of Health Promotion, Seoul, Korea.
FAU - Hwang, Inhwan
AU  - Hwang I
AD  - Department of Laboratory Medicine and Health Promotion Research Institute, Korea 
      Association of Health Promotion, Seoul, Korea.
FAU - Cho, Han-Ik
AU  - Cho HI
AD  - MEDIcheck LAB, Korea Association of Health Promotion, Seoul, Korea.
LA  - eng
PT  - Journal Article
DEP - 20210803
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amyloid beta-Peptides/*blood/*chemistry
MH  - Biomarkers/*blood
MH  - Cognitive Dysfunction/blood/*diagnosis/epidemiology
MH  - Female
MH  - Healthy Volunteers
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Reference Values
MH  - Republic of Korea/epidemiology
MH  - Risk Factors
PMC - PMC8418474
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - cognitive assessment
OT  - multimer detection system
OT  - oligomeric amyloid-beta
OT  - reference interval
COIS- No potential conflicts of interest relevant to this article were reported.
EDAT- 2021/08/04 06:00
MHDA- 2022/01/18 06:00
PMCR- 2021/08/03
CRDT- 2021/08/03 08:55
PHST- 2021/07/20 00:00 [revised]
PHST- 2021/07/02 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/08/04 06:00 [pubmed]
PHST- 2022/01/18 06:00 [medline]
PHST- 2021/08/03 08:55 [entrez]
PHST- 2021/08/03 00:00 [pmc-release]
AID - JCLA23933 [pii]
AID - 10.1002/jcla.23933 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2021 Sep;35(9):e23933. doi: 10.1002/jcla.23933. Epub 2021 Aug 3.